Bristol-Myers Squibb Co (LIM:BMY) Long-Term Debt: $42,152 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIM:BMY Bristol-Myers Squibb Co LIM:BMY
57 GF Score
Price $56.98
GF Value $48.21
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Long-Term Debt?

Bristol-Myers Squibb Co LIM:BMY 57 Long-Term Debt is $42,152 Mil as of Mar. 2026. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $48.21 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bristol-Myers Squibb Co's Long-Term Debt for the quarter that ended in Mar. 2026 was $42,152 Mil.

Bristol-Myers Squibb Co's quarterly Long-Term Debt declined from Sep. 2025 ($44,469 Mil) to Dec. 2025 ($42,850 Mil) and declined from Dec. 2025 ($42,850 Mil) to Mar. 2026 ($42,152 Mil).

Bristol-Myers Squibb Co's annual Long-Term Debt increased from Dec. 2023 ($36,653 Mil) to Dec. 2024 ($47,603 Mil) but then declined from Dec. 2024 ($47,603 Mil) to Dec. 2025 ($42,850 Mil).

Bristol-Myers Squibb Co  (LIM:BMY) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bristol-Myers Squibb Co Long-Term Debt Related Terms

Bristol-Myers Squibb Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Long-Term Debt Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39,605.00 35,056.00 36,653.00 47,603.00 42,850.00

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46,157.00 44,470.00 44,469.00 42,850.00 42,152.00
LIM:BMY
57GF Score
Bristol-Myers Squibb Co LIM:BMY
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $42,152 Mil mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Long-Term Debt of $42,152 Mil as of Mar. 2026.
Is Bristol-Myers Squibb Co's Long-Term Debt too high?
Bristol-Myers Squibb Co's current Long-Term Debt is $42,152 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Long-Term Debt compare to PFE and GILD?
Bristol-Myers Squibb Co's Long-Term Debt of $42,152 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bristol-Myers Squibb Co's current Long-Term Debt is $42,152 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.21, compared to a current price of $56.98 — trading 18.2% above its estimated fair value. The current Long-Term Debt is $42,152 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Long-Term Debt is $42,152 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of $56.98 is trading 18.2% above its estimated GF Value™ of $48.21. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for LIM:BMY:

  • Long-Term Debt: $42,152 Mil
  • GF Value™: $48.21 vs. price of $56.98 (18.2% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score

Get the complete analysis for LIM:BMY

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$48.21
GF Value